From the Journals

Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Patients who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events.

Share

The Retina Minute discusses the PULSAR extension trial, which evaluated 8 mg aflibercept vs. the conventional 2 mg dose in patients with neovascular age-related macular degeneration (AMD). The study showed that those who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events over 3 years. The high-dose aflibercept demonstrated benefits in treating neovascular AMD up to 3 years, providing insights for clinical practice.

Original Source(s)

Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Patients who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events.

  • by Tien Wong, MD, PhD, Michael A. Singer, MD

  • January 1, 2025

  • 6 min

Related Content

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA

Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.